[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Esbjerg Hospital - University Hospital of Southern Denmark\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":369},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,50,78,107,130,157,188,220,248,276,298,322,344],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100627788","transabdominal-and-laparoscopic-ultrasound-in-a-bariatric-setting-100627788",false,"NCT07453186","Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting","Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting: Utility and Diagnostic Accuracy","Inclusion Criteria:\n\n* Age ≥18 years\n* Scheduled for bariatric surgery\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous cholecystectomy\n* Previous biliary surgery\n* Previous liver surgery\n* Inability to provide informed consent",true,"ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","Every year, many patients undergo weight-loss (bariatric) surgery. While this surgery leads to significant and intended weight loss, it also increases the risk of developing gallstones or other gallbladder problems.\n\nApproximately one in five patients later requires a second operation to remove the gallbladder. This type of surgery carries a higher risk of complications and reoperations compared with gallbladder surgery performed in the general population.\n\nPreventive treatment may help reduce this risk. One option is medical treatment with Ursochol, which has been shown to lower the risk of developing gallstones after bariatric surgery. However, this treatment is only effective in patients who have not already developed gallstones before surgery.\n\nThis means patients need a reliable preoperative ultrasound examination of the gallbladder. Unfortunately, performing ultrasound can be technically challenging in patients with obesity, making it harder to detect small stones or other abnormalities.\n\nThe goal is therefore to improve the examination of the gallbladder in patients undergoing bariatric surgery in order to better identify who may benefit from preventive treatment.\n\nThe study\n\nThe investigators are comparing two types of ultrasound examination of the gallbladder:\n\n* Standard ultrasound performed on the outside of the abdomen using a handheld probe.\n* Laparoscopic ultrasound performed during bariatric surgery using a small ultrasound probe placed inside the abdomen, typically placed on the liver near the gallbladder.\n\nIt is of interest to find out whether the ultrasound performed during surgery finds more:\n\n* Gallstones\n* Sludge\n* Small stones (microlithiasis)\n* Thickening of the gallbladder wall\n\nBy improving detection, the investigators aim to better guide preventive treatment and reduce the need for future gallbladder surgery.",[27,28,29],"Gallstone Disease","Ultrasonic Diagnosis","Bariatric Patients Undergoing Bariatric Surgery",[31,32,33,34,35,36],"Bariatric surgery","Gallstone disease","Metabolic surgery","Biliary disease","Ultrasound","Laparoscopic ultrasound","RECRUITING","2026-05-29",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":41},"2026-04-01",{"date":45,"type":21},"2029-03-01",{"name":47,"class":48},"Esbjerg Hospital - University Hospital of Southern Denmark","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100533156","recovering-from-bariatric-surgery-the-effects-of-early-initiated-and-supervised-mobilization-100533156","NCT06222151","Recovering From Bariatric Surgery: the Effects of Early Initiated and Supervised Mobilization","Inclusion Criteria:\n\n* The ability to read and understand the Danish language\n\nExclusion Criteria:\n\n* Preoperative dependence of walking aids\n* Vision impairment\n* Previous syncopes or epilepsy\n* Admission to the intensive care unit after surgery\n* Acute complications during hospital admission\n* Patients are excluded at baseline if they have an oxygen saturation below 90% or a systolic blood pressure above 180 mmHg","70 Years",{"count":58,"type":21},112,[24],"The aim is to investigate the effect of early initiated and supervised mobilization continued after discharge as management of postoperative pain and recovery following obesity surgery, including patient experiences, pain coping, physical functionality and quality of life.",[62,63,64,65,66],"Postoperative Pain, Acute","Postoperative Pain, Chronic","Bariatric Surgery","Mobilization","Physical Activity",[68,64,69,66,65],"Pain Coping","Postoperative Pain","2026-05-18",{"date":72,"type":41},"2026-05-20",{"date":74,"type":41},"2024-04-22",{"date":76,"type":21},"2027-12-26",{"name":47,"class":48},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100627927","the-effect-of-music-during-colonoscopy-100627927","NCT07454993","The Effect of Music During Colonoscopy","The Effect of Music During Colonoscopy: A Randomized Controlled Trial on Pain","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled for ambulatory (outpatient) colonoscopy\n* Able to provide written informed consent\n* Able to understand and read Danish\n\nExclusion Criteria:\n\n* Planned colonoscopy under propofol sedation or general anesthesia\n* Planned endoscopic mucosal resection (EMR)",{"count":86,"type":21},1042,[24],"Colonoscopy is an important examination used to diagnose conditions such as inflammatory bowel disease and colorectal cancer and plays a central role in colorectal cancer screening programs. Although colonoscopy is a routine and generally safe procedure, many patients experience pain, discomfort, and anxiety during the examination. Approximately 25-30% of patients report moderate to severe pain. Fear of discomfort is also a known barrier to participation in colonoscopy, particularly in screening settings.\n\nSedatives and pain-relieving medications are commonly used during colonoscopy to reduce discomfort. However, medication does not completely eliminate pain or anxiety for all patients. Therefore, it is important to investigate non-pharmacological interventions that may improve patient comfort without adding risk.\n\nListening to music has been shown in various medical settings to reduce stress, anxiety, and perceived pain. Some previous studies have suggested that music during colonoscopy may reduce pain and anxiety, but results have been inconsistent and many studies have included relatively small numbers of participants. Larger, well-designed randomized trials are needed to clarify whether music has a meaningful clinical effect during colonoscopy.\n\nThe aim of this study is to investigate whether playing music during colonoscopy reduces patient-reported pain.\n\nThis study is a single-center, randomized controlled clinical trial. Patients scheduled for ambulatory colonoscopy will be randomly assigned in a 1:1 ratio to either colonoscopy with music (intervention group) or colonoscopy without music (control group). Randomization will be performed using variable block sizes to ensure balanced allocation between groups.\n\nIn the intervention group, pop and rock music from a pre-designed playlist will be played from the start to the end of the colonoscopy. The music will be clearly audible but will not interfere with communication between the patient and healthcare staff. The volume may be adjusted as needed, and the music can be turned off at any time at the request of the patient or staff.\n\nApart from the presence or absence of music, the colonoscopy procedure will be performed according to standard practice in both groups. There will be no changes to sedation, monitoring, or medical treatment as part of the study.\n\nData will be collected prospectively in two ways. During the procedure, healthcare staff will record procedure-related information, including medications administered and their assessment of the patient's pain using a numeric rating scale (0-10). After the procedure, and before discharge, patients will complete a short electronic questionnaire, also rating their pain on a 0-10 numeric rating scale. The questionnaire will be completed regardless of whether the procedure was fully completed or what findings were observed.\n\nThe study plans to include a total of 1,042 participants (521 in each group). The primary outcome is the difference in patient-reported pain between colonoscopy performed with music and colonoscopy performed without music.\n\nPlaying music during colonoscopy is considered a low-risk intervention. If a patient finds the music uncomfortable or disturbing, it will be stopped immediately. Participation in the study will not otherwise affect the patient's treatment or care.\n\nIf music is shown to reduce pain during colonoscopy, it may represent a simple, inexpensive, and easily implementable method to improve patient comfort during this common procedure.",[90,91],"Pain","Pain Management",[93,94,95,96,97,98],"pain","colonoscopy","music","procedural pain","pain management","colorectal cancer screening","2026-03-13",{"date":101,"type":41},"2026-03-16",{"date":103,"type":41},"2026-03-12",{"date":105,"type":21},"2026-11-30",{"name":47,"class":48},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":49},"100585001","cortisol-and-obesity---a-vicious-cycle-hypoglycemia-after-bariatric-surgery---association-with-cortisol-metabolism-100585001","NCT06896682","Cortisol and Obesity - A Vicious Cycle? Hypoglycemia After Bariatric Surgery - Association With Cortisol Metabolism?","Inclusion Criteria:\n\nParticipants must have undergone one of the following bariatric procedures at least 12 months prior:\n\n* Roux-en-Y gastric bypass\n* Gastric sleeve\n\nExclusion Criteria\n\n* Pregnancy and breastfeeding\n* Nephrotic syndrome (kidney disease with protein loss in urine), liver cirrhosis, or severe malnutrition, as these conditions reduce cortisol-binding globulin (CBG) levels, affecting total cortisol concentration\n* Use of corticosteroid medications, such as prednisolone\n* Use of opiod-containing medication\n* Use of medications containing estrogen, such as hormone therapy for menopause\n* Known adrenal disease affecting cortisol metabolism, including autonomous cortisol production and Cushing's syndrome\n* Diabetes that does not require medical treatment\n* Previously diagnosed reactive hypoglycemia after bariatric surgery requiring medical treatment",{"count":114,"type":21},100,"OBSERVATIONAL","The goal of this observational study is to learn about how bariatric surgery affects the metabolism of cortisol.\n\nThe main question it aims to answer is whether changes in cortisol contribute to the development of reactive hypoglycemia?\n\n100 individuals who have previously undergone bariatric surgery, are planned to be included.",[118],"Postbariatric Hypoglycemia",[120,121,122],"cortisol","bariatric surgery","postbariatric hypoglycemia","2026-03-11",{"date":99,"type":41},{"date":126,"type":41},"2025-07-08",{"date":128,"type":21},"2026-12-31",{"name":47,"class":48},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100620771","oral-versus-intravenous-fluid-therapy-in-the-emergency-department-100620771","NCT07361952","Oral Versus Intravenous Fluid Therapy in the Emergency Department","OVID-B","Inclusion Criteria:\n\n* Age 18 or above\n* At least 1000 ml of crystalloid fluid therapy prescribed by the physician\n\nExclusion Criteria:\n\n* Altered mental state prohibiting oral fluid intake (Glasgow Coma Scale ≤ 12)\n* Pregnancy\n* Oral fluids contraindicated (e.g. bowel obstruction)\n* Severe hyponatremia (sodium \\\u003C120 mEq\u002FL)\n* Requiring treatment in the intensive care unit",{"count":138,"type":21},250,[24],"The goal of this randomized clinical feasibility trial is to determine whether oral fluid therapy can achieve prescribed fluid volumes as effectively as intravenous fluid therapy in adult patients admitted to the emergency department who require fluid treatment.\n\nThe main questions it aims to answer are:\n\nAre patients receiving oral fluids equally likely to achieve the prescribed fluid volume compared with patients receiving intravenous fluids?\n\nIs it feasible to conduct a randomized trial of oral versus intravenous fluid therapy in the emergency department, based on recruitment rate and protocol adherence?\n\nResearchers will compare oral tap water administration with standard intravenous crystalloid therapy to assess whether oral fluids are non-inferior in achieving prescribed fluid volumes and to evaluate feasibility outcomes.\n\nParticipants will:\n\nBe randomized to receive either oral tap water or intravenous crystalloid fluids during their stay in the emergency department\n\nReceive a fluid volume and administration rate determined by the treating physician\n\nBe monitored according to standard clinical practice during the emergency department stay\n\nHave fluid intake, vital signs, and clinical outcomes recorded, with follow-up through routine health records up to 30 days after inclusion",[142],"Fluid Management",[144,145,146,147],"oral fluids","Emergency department","intravenous fluids","fluid management","2026-01-22",{"date":150,"type":41},"2026-01-23",{"date":152,"type":41},"2025-10-03",{"date":154,"type":21},"2026-07",{"name":47,"class":48},3,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":168,"studyType":115,"phases":4,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100620131","what-influence-re-participation-in-the-danish-colorectal-screening-program-100620131","NCT07353632","What Influence Re-participation in the Danish Colorectal Screening Program.","Re-participation for Screening-colonoscopy - Experience of colonoscpy_1","Inclusion Criteria:\n\n* Adults undergoing screening-derived colonoscopy as part of the Danish colorectal cancer screening program\n* Written informed consent\n\nExclusion Criteria:\n\n* Inability to understand or communicate in Danish\n* Lack of decision-making capacity, including cognitive impairment due to dementia or brain injury\n* Declines or withdraws informed consent","50 Years","75 Years",{"count":167,"type":21},8000,"3 Years","This prospective observational study investigates how participants experience screening colonoscopy within the Danish colorectal cancer screening program and how these experiences relate to clinical findings, procedural factors, and future participation in screening.\n\nThe study aims to evaluate patient-reported experiences such as pain, discomfort, preparation burden, emotional responses, and perceptions of healthcare staff, as well as staff-assessed pain during the procedure. These experiences will be examined in relation to colonoscopy findings, including polyp detection, histology, risk stratification, and colorectal cancer detection. In addition, procedure-specific variables such as insertion time, bowel preparation quality, completeness of colonoscopy, medication use, and adenoma detection rate will be analyzed in relation to patient experience.\n\nA key focus is whether the experience of screening colonoscopy influences subsequent participation in the colorectal cancer screening program, particularly among individuals classified as low risk and re-invited for screening after two years. Registry-based follow-up will be used to assess re-participation.\n\nData are collected prospectively from two sources: (1) real-time procedure data entered by healthcare staff during colonoscopy and (2) patient-reported outcomes collected via a questionnaire completed shortly after the procedure. Additional outcome data are obtained from electronic medical records and national health and screening registries.\n\nThe study has no single predefined hypothesis. Instead, it serves as a data-generating platform designed to address both predefined and future research questions related to screening colonoscopy experiences, quality indicators, and screening adherence.",[171,172,90],"Colonoscopy","Screening Colonscopy",[174,175,176,177,178],"Screening colonoscopy experience","Colorectal cancer screening","Patient-reported outcomes","Pain perception during colonoscopy","Screening re-participation","2026-01-19",{"date":181,"type":41},"2026-01-20",{"date":183,"type":41},"2024-09-23",{"date":185,"type":21},"2027-06-30",{"name":47,"class":48},8,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100593494","phase-2-mediterranean-diet-and-inequality-in-early-breast-cancer-100593494","NCT07007169","Mediterranean Diet and Inequality in Early Breast Cancer","Mediterranean Diet and Inequality in Early Breast Cancer: A Multicenter Randomized Clinical Trial","MEDITERRACARE","Inclusion Criteria:\n\n1. Signed written informed consent approved by the Ethical Review Board.\n2. Age ≥ 18\n3. Histologically confirmed unilateral adenocarcinoma of the breast, stage I-III, candidates for neoadjuvant chemotherapy followed by curative surgery, or adjuvant chemotherapy after curative surgery, according to the Danish Breast Cancer Group guidelines 48. The addition of trastuzumab and pertuzumab in HER2-positive tumors, or pembrolizumab in triple-negative tumors, per Danish Breast Cancer Group guidelines 48, is allowed as an adjunct to chemotherapy.\n4. Good performance status (WHO performance status 0 or 1).\n5. Willingness by the patient to undergo treatment and study-related procedures according to the protocol.\n6. Have a smartphone or computer to which it is possible to receive emails (for food diary; www.myfood24.org)\n7. Must be willing to restrict from probiotic (living microorganisms) supplements during the study. Fermented foods are allowed.\n\n   \\-\n\nExclusion Criteria:\n\n1. Clinical or radiological signs of metastatic disease.\n2. History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin cancer.\n3. Previous chemotherapy for cancer or other malignant disease.\n4. Major altered digestive system disorders (e.g. gastric by-pass or Crohn's disease or ulcerative colitis)\n5. Unable to communicate effectively in Danish or English.",{"count":197,"type":21},105,[199],"PHASE2","Social determinants such as education, income, marital status, and social networks play a crucial role in cancer outcomes, including breast cancer. One potential influencing factor is diet, and the Mediterranean diet has been shown to benefit both the health and the microbiome.\n\nThis raises the question: Does adherence to the Mediterranean diet impact the microbiome, quality of life, overall well-being, and outcomes in breast cancer patients undergoing (neo)adjuvant treatment, particularly among those with unfavorable socioeconomic determinants?\n\nThe Mediterranean diet consists of plant foods such as vegetables, fruits, nuts, seeds, berries, legumes, herbs, and spices. It also features animal proteins like fish, meat, and cheese, along with fat from olive oil. Thus, adherence to the Mediterranean diet is adherence to the official Danish diet recommendations.\n\nThis phase II clinical trial is an interdisciplinary study combining nutrition, sociology, and health research. Breast cancer patients candidates for (neo)adjuvant treatment at four oncology departments in Region South Denmark will be randomized 2:1 to the Mediterranean diet (with individual dietary guidance from a nutrition therapist aiming at daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food) versus the patient's regular diet, in conjuction with the (neo)adjuvant chemotherapy.\n\nThe trial's primary endpoint will be changes in gut microbiota composition in feces.\n\nThe study evaluates how the Mediterranean diet affects the microbiota (evaluated using Oxford Nanopore Technology 16S sequencing on fecal samples); short-chain fatty acids in stool and plasma (assessed by mass spectrometry); immune system (using flow cytometry for immune cell determination in blood and immunohistochemical determination of immune cells in the tumor tissue); and patients' social quality of life, overall well-being, sense of empowerment, and personal feeling of agency (using the WHOQOL-100 questionnaire); taking into account the impact of the distance from the patient residence to the hospital (tracked from GEOTEAM at Statistics Denmark), and socioeconomic factors (using the DREAM database).\n\nThe evaluation of biological parameters is based on the suggested mechanism of action. A diet rich in various plant foods and dietary fiber will alter the gut microbiota, promoting bacteria producing high amounts of short-chain fatty acids. These fatty acids will activate immune cells, aiding in the destruction of cancer cells.\n\nThe study will also assess whether the Mediterranean diet will positively impact the patients' social quality of life, overall well-being, sense of empowerment, and personal feeling of agency. The Mediterranean diet may not only lead to improved dietary habits but also serve as a crucial tool for breast cancer patients, particularly among those with unfavorable socioeconomic determinants. Enhanced empowerment and improved coping tools could be an important step in combating cancer-related inequalities.",[202],"Early Breast Cancer",[204,205,206,207,208,209,210],"Microbiome","Mediterranean Diet","Inequality in cancer","Chemotherapy","Adjuvant","Neoadjuvant","Short-chain Fatty Acids","2025-12-29",{"date":213,"type":41},"2026-01-02",{"date":215,"type":41},"2025-03-27",{"date":217,"type":21},"2036-03",{"name":47,"class":48},2,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":49},"100576817","glucose-dependent-insulinotropic-polypeptide-effect-on-bone-remodelling-and-cell-activity-ginebra-100576817","NCT06790225","Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)","GINEBRA","Inclusion Criteria:\n\n* healthy volunteers\n\nExclusion Criteria:\n\n* pre-diabetes or diabetes (HbA1c \\>42mmol\u002Fmol)\n* BMI \\>28\n* fractures with \\\u003C 6months\n* comorbidities\u002Ftreatments that may influence bone metabolism or procedures - -- pregnancy\n* inability to provide informed concent","40 Years",{"count":229,"type":21},12,[24],"Glucose-dependent insulinotropic polypeptide (GIP) is released by the intestines in response to food intake and increases insulin secretion. Although short-term (\\\u003C 3 hours) stimulation with GIP decreases bone resorption in humans, the effect may vanish following continuous administration within 24 hours, at least in patients with type 1 diabetes. Whether the anti-resorptive effect of GIP can be maintained if the hormone is non-continuously administrated is unclear. As the first GIP receptor (GIPR) agonist, tirzepatide was recently approved for the treatment of obesity and type 2 diabetes in the USA and type 2 diabetes alone in the EU, there is a need to establish knowledge about the long-term effects of GIP on bone health, including if different exposure times to GIP have different skeletal effects.\n\nThis project will investigate whether GIP maintains its anti-resorptive potential if given as intermittent compared to continuous infusion in healthy men and women aged 18-40 years. Administration cycles involve intermittent (8 hours daily) and continuous (24 hours daily) injection of GIP for three days each. The effect of GIP will be measured by bone markers in blood samples, as well as in vitro activity and genetic alterations of bone cells (osteoclasts and osteoblasts) using bone marrow aspirates and bone marrow biopsies. Each participant will receive both administration cycles using a crossover design with a 14-28 days washout period between administrations of GIP.",[233,234,235],"Bone Disease, Metabolic","Diabetes Mellitus, Type 2","Obesity and Obesity-related Medical Conditions",[237,238,239,240,241],"GIP","CTX","P1NP","Glucose-dependent insulinotropic polypeptide","Bone remodelling",{"date":213,"type":41},{"date":244,"type":41},"2025-11-10",{"date":246,"type":21},"2027-11-30",{"name":47,"class":48},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":227,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":275},"100583950","feasibility-of-a-minimally-invasive-diagnostic-algorithm-in-suspected-crohns-disease-100583950","NCT06882993","Feasibility of a Minimally Invasive Diagnostic Algorithm in Suspected Crohn's Disease","Feasibility of a Minimally Invasive Diagnostic Algorithm in Suspected Crohn's Disease - a Prospective Comparison of Pan-Enteric Capsule Endoscopy Versus Ileocolonoscopy Plus MR Enterography or Small-Bowel Capsule Endoscopy","ANDI-3","Inclusion Criteria:\n\n* Clinical suspicion of CD\\*\n* Age 18-40 years\n* Signed informed consent\n\n  \\*A clinical suspicion of CD is based on the following definition:\n* Diarrhea and\u002For abdominal pain for more than 1 month (or repeated episodes of diarrhea and\u002For abdominal pain) and either\n\n  * fecal calprotectin ≥ 200 mg\u002Fkg or\n  * fecal calprotectin ≥ 50 mg\u002Fkg plus one or more of the following findings:\n* C-reactive protein (CRP) \\> 5 mg\u002FL\n* Thrombocytosis (\\> 400 x 109\u002FL)\n* Anemia (hemoglobin \\\u003C 7.0 mmol\u002FL for women and \\\u003C 8.0 mmol\u002FL for men or a decrease \\> 0.5 mmol\u002FL compared to the usual level)\n* Prolonged fever (\\> 37.5 ◦C for more than 2 weeks)\n* Weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight)\n* Perianal abscess \u002F fistula\n* Family history of inflammatory bowel disease.\n\nExclusion Criteria:\n\n* Previous intestinal resection\n* Positive serologic markers for celiac disease\n* Positive stool polymerase chain reaction for pathogenic bacteria\n* Positive stool polymerase chain reaction for intestinal parasites\n* Suspected or established acute bowel obstruction (ileus)\n* Intake of NSAIDs or acetylsalicylic acid ≤ 4 weeks before inclusion, except low-dose, prophylactic acetylsalicylic acid (≤ 150 mg per day)\n* Intake of opioid or opioid-like medications ≤ 1 week before inclusion\n* Pregnancy or lactation\n* Inability to comply with protocol requirements, e.g. for reasons including alcohol or recreational drug abuse\n* Known gastrointestinal disorder other than functional gastrointestinal disorders\n* Renal failure defined by a plasma-creatinine above the normal reference range",{"count":257,"type":21},165,[24],"The goal of this clinical trial is to learn whether a camera pill examination of the whole bowel can be used to diagnose Crohn's disease instead of colonoscopy and a small bowel examination (either MRI or camera pill) in patients aged 18-40 years suspected of having Crohn's disease.\n\nThe main question it aims to answer is:\n\nHow many patients examined with a camera pill examination of the whole bowel will have a complete examination of the whole bowel and have a diagnosis made without need for any more examinations?\n\nResearchers will compare with patients examined with colonoscopy and a small bowel examination.\n\nParticipants will:\n\n* Be examined with either a camera pill examination of the whole bowel, or a colonoscopy and a small bowel examination\n* Have their electronic medical records checked to see if a diagnosis has been made\n* Have an interview every three months if diagnosed with an inflammatory bowel disease or after a year if no disease was found",[261],"Crohn's Disease",[263,264,265,266],"capsule endoscopy","panenteric capsule endoscopy","Crohn's disease","inflammatory bowel disease","2025-03-17",{"date":269,"type":41},"2025-03-19",{"date":271,"type":41},"2025-02-26",{"date":273,"type":21},"2028-08-31",{"name":47,"class":48},5,{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":49},"100538306","predictive-utility-of-a-short-term-improvement-in-objectively-measured-physical-activity-in-rheumatoid-arthritis-pusipa-100538306","NCT06289114","Predictive Utility of a Short-term Improvement in Objectively Measured Physical Activity in Rheumatoid Arthritis (PUSIPA)","Predictive Utility of a Short-Term Improvement in Objectively Measured Physical Activity in Rheumatoid Arthritis Patients Initiating Biologics: A Prospective Cohort Study","PUSIPA","Inclusion Criteria:\n\n* Patients with RA (\\> 18 years of age)\n* Patients who are to be treated with a biological agent\n* Patients who can read and understand Danish\n\nExclusion Criteria:\n\n* Patients who are physically impaired (patients depending on assistance devices for walking)\n* Pregnancy\n* Patients who have received corticosteroids two weeks prior to and during the period of the movement measurement\n* Patients who by virtue of illiteracy or cognitive impairment, are unable to complete the questionnaire.",{"count":114,"type":21},"SUMMARY Background: Several studies have shown physical activity (PA) to be inversely correlated to disease activity in rheumatoid arthritis (RA) patients. However, it is unclear whether improved PA leads to lower disease activity or if low disease activity predicts improved PA in rheumatoid arthritis patients. Furthermore, it is unknown how fibromyalgia (FM) affects this interaction.\n\nObjective(s): Our primary objective will be to compare the effect of an immediate improvement in physical activity after one week on the proportion of RA patients achieving low disease activity after 12 weeks of biological treatment. Furthermore, we will explore whether the presence of concomitant FM affects this clinical response (i.e., interaction between FM status and PA response).\n\nDesign: A prospective cohort study in the form of a target-trial attempting to address a causal question comparing the outcome among the participants with an immediate improvement in physical activity, relative to individuals without.\n\nSetting and patients: Biologically naive RA patients initiating biological treatment are consecutively enrolled. PA is quantified by accelerometry one week prior to, one week after, and after 3 months of biological treatment.\n\nSample size: 100 RA patients starting biological therapy is planned enrolled in the study.\n\nMeasurements: RA patients will be divided into two groups depending on their improvement in physical activity after onset of biological treatment. The percentage of time spent in moderate-to-vigorously physical activity (MVPA) i.e., the percentage of time a patient is in motion \\[walking, running, bicycling, or swimming\\] is measured prior to, one week, and approximately 3 months after biological treatment onset, respectively. The MVPA ratio (MVPA After biological treatment\u002FMVPA Before biological treatment) will divide patients enabling a contrast between two groups: Those with high improvement considering MVPA (after 1 week; the upper tertile of MVPA ratio of the sample) and those without. Treatment response (achieving a disease activity score \\\u003C 3.2) after approximately 3 months from baseline will be analyzed as the contrast between groups.",[287,288,289,290],"Rheumatoid Arthritis","Fibromyalgia, Secondary","Fatigue","Physical Inactivity","2025-03-13",{"date":267,"type":41},{"date":294,"type":41},"2023-09-01",{"date":296,"type":21},"2025-09-01",{"name":47,"class":48},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":49},"100326828","prognostic-significance-of-fatty-liver-disease-in-bariatric-patients-100326828","NCT03535142","Prognostic Significance of Fatty Liver Disease in Bariatric Patients","PROMETHEUS","Inclusion Criteria case group:\n\n* Age \\> 18 years\n* BMI \\>35 kg\u002Fm2 and referred for bariatric surgery at Hospital of South West Jutland, Denmark\n* Able to give written informed consent.\n\nInclusion criteria control group:\n\n* Age \\> 18 years\n* BMI \\>35 kg\u002Fm2 with no wish to undergo bariatric surgery.\n* Able to give written informed consent.\n\nExclusion Criteria:\n\n* Active viral hepatitis\n* Not willing or able to consent\n* Contraindications to liver biopsy",{"count":306,"type":21},1200,[24],"Prospective non-randomized intervention case control study on patients with a BMI \\> 35. The intervention group\u002Fcases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age, weight and comorbidity matched patients who choose not to undergo bariatric surgery. The overall aim is to examine prevalence of the spectrum of fatty liver disease (NAFLD) in these patients and the prognostic significance of NAFLD.",[310,311,312,313],"Non-Alcoholic Fatty Liver Disease","Metabolic Encephalopathy","Obesity, Morbid","Non-alcoholic Steatohepatitis","2025-03-03",{"date":316,"type":41},"2025-03-05",{"date":318,"type":41},"2018-08-15",{"date":320,"type":21},"2038-04-01",{"name":47,"class":48},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":335,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":4},"100551931","non-pharmacological-treatment-of-patients-at-risk-of-developing-persistent-posttraumatic-headache-100551931","NCT06466499","Non-pharmacological Treatment of Patients at Risk of Developing Persistent Posttraumatic Headache","Inclusion criteria:\n\n* Clinical diagnosed with acute posttraumatic headache\n* Headache present for more than 15 days\u002Fmonth\n* Must understand written and spoken Danish\n\nExclusion criteria:\n\n* History of pre-existing primary or secondary headache\n* Dementia or comorbidity with neurological disorders\n* Psychiatric disorders\n* Participants who cannot collaborate in relation to the intervention","60 Years",{"count":330,"type":21},104,[24],"The goal of this mixed method study is to test and evaluate the effect of an early interdisciplinary non-pharmacological treatment of patients at risk of developing persistent posttraumatic headache in order to prevent the development of persistent posttraumatic headache and thereby, reduce persistency and improve the quality of life. Furthermore, to gain knowledge on and a deeper understanding of the patients' perspective and experience of the treatment.\n\nThe project consists of 3 sub studies:\n\n1. A feasibility study; with the purpose of exploring the feasibility of an early non-pharmacological intervention for patients with persistent posttraumatic headache after mild traumatic brain injury.\n2. An experimental design; a randomized controlled trial to evaluate the effect of the early non-pharmacological treatment.\n3. A qualitative focus group interview study; to get a more nuanced knowledge of patients' experience with the non-pharmacological treatment related to post traumatic headache.",[334],"Posttraumatic Headache","NOT_YET_RECRUITING","2024-11-27",{"date":338,"type":41},"2024-12-02",{"date":340,"type":21},"2024-12-01",{"date":342,"type":21},"2027-05-05",{"name":47,"class":48},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":352,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":355,"conditions":356,"keywords":359,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":49},"100530079","intraoperative-administration-of-intravenous-morphine-in-patients-undergoing-laparoscopic-cholecystectomy-100530079","NCT06182111","Intraoperative Administration of Intravenous Morphine in Patients Undergoing Laparoscopic Cholecystectomy","Intraoperative Administration of Intravenous Morphine in Patients Undergoing Laparoscopic Cholecystectomy - a Retrospective, Observational, Quality-improvement Study","MORPHLAPCHOL","Inclusion Criteria:\n\n* patients who have had elective laparoscopic cholecystectomy\u002Fplanned gall-bladder removal surgery\n\nExclusion Criteria:\n\n* age limit as above\n* patients unable to give consent to anesthesia\n* patients unable to participate in pain scoring\n* patients with chronic pain syndromes, characterized by patients receiving regular analgesic treatment and patients with active or previous contact to pain clinic)\n* patients with active or previous substance abuse\n* emergency surgery","21 Years",{"count":354,"type":21},300,"The goal of this observational, quality improvement study is to compare the effect of a dose of morphine given during gall-bladder removal surgery. The main questions to answer are:\n\n* Do participants, who are given given a dose of morphine during gall-bladder removal surgery, experience less pain after surgery?\n* Does a dose of morphine during gall-bladder removal surgery cause more side effects? The investigators will compare the effects of two types of anesthesia: a) anesthesia without morphine during surgery, and b) anesthesia with morphine during surgery.",[69,357,358],"Morphine","Laparoscopic Cholecystectomy",[360],"Intraoperative morphine for laparoscopic cholecystectomy","2024-08-27",{"date":363,"type":41},"2024-08-28",{"date":365,"type":41},"2024-06-01",{"date":367,"type":21},"2025-10-31",{"name":47,"class":48},""]